Background: Bax, a proapoptotic protein but its regulation during oral cancer progression and resistance remains elusive. Methods: A total of 127 samples including adjacent normal, primary tumor, and resistance to chemoradiation therapy (RCRT) samples from oral squamous cell carcinoma (OSCC) patients were used. The status of Bax was analyzed at DNA/mRNA/protein levels and the results were correlated with p53 and Akt expression in tissue samples/ cisplatin-resistant oral tongue SCC (SCC9/SCC4-CisR) cell line. Results: Frequent progressive decrease of Bax expression with infrequent promoter methylation, polymorphisms G(-248)A, and mutations was observed in OSCC progression/resistance. Furthermore, by targeting Akt pathway, induction of Bax-dependent cell death was observed and this was further enhanced with nimbolide treatment in SCC9/SCC4-CisR cells. Conclusion: Hence, the Bax gene alteration and its deregulation through p53/Akt pathway are important for OSCC progression and drug resistance. Akt Inhibitor VIII and nimbolide synergistically induce Bax, and it is therefore beneficial for chemosensitizing cisplatin-resistant human OSCC.
gene are very common, resulting in loss of the tumor suppressor function. 13, 14 Mutations in the promoter and coding regions of the Bax gene have been reported in head and neck SCC (HNSCC). 15, 16 A single nucleotide polymorphism (SNP, G-248A; rs 4645878) was associated with reduced protein expression and failure to achieve complete response. 17, 18 The homozygous AA genotype of BAX G(-248)A was found to be associated with an elevated risk of HNSCC. 16 P53, a well-known tumor suppressor protein is involved in the induction of Bax-mediated apoptosis, 19 whereas mutant p53 is associated with cisplatin resistance in oral cancer. 20 P53
regulates the transcription of Bax gene and the loss of p53 function causes diminished expression of Bax. [21] [22] [23] Alteration of protein kinase B (PKB/Akt) activity has been demonstrated in human cancers including OSCC. [24] [25] [26] Akt-mediated regulation of the proapoptotic proteins Bax and caspase-3 has been documented in OSCC 27 and is linked with drug resistance. 28, 29 Bax protein, an independent predictor of OSCC, is known to respond to anticancer agents 30, 31 and influences intrinsic cisplatin sensitivity in head and neck cancer cell lines. 32 Recently, we demonstrated that nimbolide, a limonoid constituent of the leaves and flowers of the neem tree (Azadirachta indica A. Juss), induces mitochondrial-mediated apoptosis in the hamster buccal pouch model of oral carcinogenesis by upregulating Bax. 33 Bax is stimulated by nimbolide causing increased cell death in nasopharyngeal SCC. 34 Although Bax expression has been shown to be an important and independent prognostic marker in OSCC, 31 the detail regulation of Bax in OSCC progression and drug resistance has not been explored. Here, overall decreased expression of Bax was observed in oral cancer progression and resistance. The effect of promoter methylation/SNP and mutations of the exons were analyzed in the tissue samples of OSCC progression and resistance. Bax protein and mRNA expression were negatively correlated with Akt activation and p53 expression. Furthermore, by targeting Akt, Bax-mediated cell death was observed in cisplatin-resistant SCC9 and SCC4 cells that were further enhanced by treatment with nimbolide. The study provides evidence that Bax is an important target for overcoming human OSCC cells as well as for resistance to chemoradiation therapy (RCRT).
| MATERIALS AND METHODS

| Patients and tissue samples
A total of 127 tissue samples obtained from OSCC patients were used for various experiments. These include 31 tumor adjacent normal samples, 69 pretreatment tumor biopsy samples (primary tumor) and 27 RCRT samples. The primary tumor and adjacent normal samples were obtained from OSCC patients before treatment, whereas RCRT samples were from patients with incidence of local recurrence after postoperative concurrent chemoradiation therapy. The specimens were collected after obtaining informed consent from the patients with the approval of the Institutional Human Ethical Committee of Central University of Jharkhand. Hematoxylin-eosin stain sections were used for histological studies and staging of these samples were conducted according to the American Joint Committee on Cancer/International Union against Cancer guidelines.
| Immunohistochemistry
Immunohistochemistry (IHC) was performed as discussed elsewhere, with various tissue samples (n = 121, 25 AN, 69 PT, and 27 RCRT). 35 The staining was done with EnVision FLEX Mini Kit (Code: K8023, DAKO; USA) and diaminobenzidine tetrachloride was used to visualize the staining. For negative control, BSA in place of the primary antibody and for positive control, the samples with confirmed immunoreactivity to a particular antibody were used. Based on the staining intensity and the extent of immunoreactivity, the immunostained samples were visualized and scored (as 0 to 4). The staining was scored in the following manner: 0 = no expression, 1-4 = expression, and 2-4 = overexpression.
| Western blot analysis
Western blot analysis was performed as previously described by us. 35 A total of 49 samples (13 AN, 19 PT, and 17 RCRT) was used. Tissue/cell lysates were prepared in RIPA buffer and protein samples (30-100 μg) were resolved using 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) with a protein marker (Catalog Number: C1992, Sigma) and transferred to PVDF membranes (by iBlot, BioRad, USA). Immunoblot analysis was performed with the following primary antibodies from Santa Cruz Biotechnology, USA, and Cell Signaling Technology, USA; like Bcl-2 (CST #15071), p53 (CST#48818), p-AktSer 473 (sc:7985-R), Bax (sc-7480), and β-actin C-4 (sc-47778). The secondary antibodies (Santa Cruz Biotechnology) were applied and the SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) was used to detect horseradish peroxidase. A developer, fixer, and X-ray film (Kodak) were used to capture the signal.
| Bisulfite conversion and Bax gene promoter methylation analysis
Bisulfite conversion and gene promoter methylation analysis was performed as previously described. 36 A total of 41 samples (11 AN, 16 PT, and 14 RCRT) were used. The genomic DNA of these OSCC samples was isolated (QIAamp DNA Mini Kit; Qiagen Cat.No-51304). Sodium bisulfite conversion of genomic DNA was performed on 1 μg DNA using an EpiTect Bisulfite kit (Qiagen Cat.No-59104) according to the manufacturer's protocol. The polymerase chain reaction (PCR) Methylation-specific PCR (MS-PCR) product (118 and 102 bp as unmethylated and methylated, respectively) was amplified by using the primers as described 37 in Supporting Information.
The extent of Bax methylation was determined based on the PCR band strength on the agarose gel.
| PCR-SSCP analysis for Bax
Nonradioactive PCR-Single-strand conformation polymorphism (SSCP) was performed in 103 samples (29 AN, 47 PT, and 27 RCRT) as described elsewhere in literature. 17 Briefly 10 μL of each PCR product with gel loading dye was denaturated at 95 C for 10 minutes and subjected to electrophoresis for 75-80 minutes at 165 v in 10% polyacrylamide gel. After electrophoresis, the gel was stained with a 0.5 mg/mL solution of ethidium bromide for 20 minutes and then washed with water for 5-10 minutes. The stained bands were visualized using GelDoc. Primers for all 6 exons of Bax gene were taken from published literature [38] [39] [40] as described in Supporting Information and the PCR-amplified products of exon-1 (131 bp), exon-2/3 (400 bp), exon-3 (94 bp), exon-4 (209 bp), exon-5 (192 bp), and exon-6 (237 bp) were confirmed on the gel.
| SNP-genotyping analysis
Genomic DNA isolated from 101 samples (31 AN, 43 PT, and 27 RCRT) was taken for genotyping of Bax at G(-248) A. The SNP of Bax promoter was determined by allelespecific PCR (AS-PCR) analysis and sequencing. The primers used to amplify a 104 bp fragment from the Bax promoter containing the G(-248)A site were designed: Bax
0 . β-globin gene was used as the internal control and amplified along with Bax promoter containing the SNP region. 41 The PCR products were subjected to electrophoresis on 1.5% agarose gel, stained with ethidium bromide, and visualized using UV GelDoc system.
| Real-time PCR analysis
Total RNA from 47 samples (13 AN, 19 PT, and 15 RCRT) was isolated using the protocol described earlier 35 
| Cell culture, treatment of inhibitors/drugs, and MTT assay
SCC9 and SCC4 cells were cultured as described before. 36 Sodium chloride (0.9%) was used to dissolve cisdichlorodiammine platinum(II)/cis-platinum(II) diammine dichloride (cisplatin; P4394, Sigma Aldrich, St. Louis, Missouri) aliquoted and stored at −20 C. Cells were rendered cisplatin resistant by selecting the cells with increasing doses of the drug, that is, with 5, 10, 15, and 30 μM of cisplatin for 1 week each, for 4 weeks. The exposure to the drug was determined by the dose incremental strategy (IC12.5 to IC50 of cisplatin) and was based on our result.
The surviving cells after each treatment were cultured in cisplatin-free medium for a period of 4-5 days. The experiments were performed with SCC9/4 as well as SCC9/4 CisR cells and cultured in 6-well plates with regular media. After 12 hours incubation in the absence of cisplatin or in presence of 25/20 μM cisplatin (in SCC9, SCC9-CisR cells; and Abbreviations: AN, adjacent normal; ns, not significant; OSCC, oral squamous cell carcinoma; PT, primary tumor; RCRT, resistance to chemoradiation therapy. Figure 1A ). Bax expression was detected in 84.6% of adjacent normal samples (11 of 13), 52.6% of primary tumor (10 of 19), and in 35.2% of the RCRT tumors (6 of 17). The decreased trend of Bax protein expression from adjacent normal to primary tumor and from adjacent normal to RCRT was found to be statistically significant ( Figure 1B) . The results of IHC analysis suggest a progressive decrease in Bax expression with oral tumor progression ( Table 1) . For most cases, the observed immune reactivity was maximum in adjacent normal, decreased/intense in primary tumor, and faint in RCRT specimens (Figure 1C -K; Supporting Information Table S1 ). Additionally, Bax overexpression was seen in 76%, 46.3%, and 29.6% of the adjacent normal (19 of 25), primary tumor (32 of 69), and RCRT (8 of 27) groups of specimens, respectively, and was found to be statistically significant ( Figure 1L ; Supporting Information Table S1 ). The representative photomicrographs of Bax expression are illustrated in Figure 1M and Supporting Information Table S1 .
| Bax mRNA expression correlates with its protein expression and promoter hypermethylation in OSCC
The Bax mRNA expression level was observed in 76.9% of the adjacent normal samples (10 of 13), whereas it was decreased in 57.8% of the primary tumor (11 of 19) cases and 33.3% of the RCRT (5 of 15) cases (Figure 2A ). The decrease in Bax mRNA expression from adjacent normal to primary tumor and from primary tumor to RCRT group was found to be significant ( Figure 2B ). Furthermore, Bax mRNA expression showed a positive correlation with Bax protein expression (P = .0001; Figure 2C ). Bax gene promoter (n = 41) methylation showed a steady increase from normal samples through primary tumor to RCRT tissue specimens ( Figure 2D ). However, a statistically significant difference in promoter methylation was seen only between adjacent normal and RCRT by one-way ANOVA (*P < .01; Figure 2E ). A negative correlation was found between Bax gene promoter methylation and Bax mRNA (P = .02; Figure 2F ) and protein expression (P = .01; Figure 2G ).
| Frequency of mutations of the Bax gene in OSCC progression and resistance
Exonic mutations of Bax gene were found in 14 of 103 samples that showed altered PCR-SSCP patterns. These included 5 in exon 2 of 3 (1 in normal, 2 in primary tumor, and 2 in RCRT samples, Figure 3C ), 4 in exon 3 that contain a microsatellite tract comprised of a cluster of 8 guanine nucleotides (G8) tract (1 in normal, 1 in primary tumor, and 2 in RCRT samples, Figure 3D ), 2 in exon 5 (1 in primary tumor and 1 RCRT samples, Figure 3F ), and 3 in exon 6 (1 in primary tumor and 2 in RCRT samples, Figure 3G ). No alterations were observed in exon-1 and exon-4 ( Figure 3B ,E). Polymorphism analysis of the Bax promoter G(-248)A (n = 101) in the adjacent normal (n = 31), primary tumor (n = 43), and RCRT (n = 27) was performed by PCR using genomic DNA as template ( Figure 3H,I ). The 5 0 extended PCR product isolated from the same DNA sample was sequence confirmed ( Figure 3J ).
| SNP, G(-248)A of BAX promoter and its association with decreased protein expression
The frequency of GG, GA, and AA genotypes of Bax promoter G(-248)A was found in 93.5% (29 of 31), 16.1% (5 of 31), and 0.0% (0 of 31) in adjacent normal; 81.3% (35 of 43), 25.5% (11 of 43), and 4.6% (2 of 43) in primary tumor; and 70.3% (19 of 27), 29.6% (8 of 27), and 7.4% (2/27) in RCRT cases, respectively (Figure 4 ). The G(-248)A polymorphism in the Bax promoter was in Hardy-Weinberg equilibrium among samples with various groups primary tumor, RCRT, and controls (adjacent normal). GA genotype was 1.823 times more prevalent in primary tumor over adjacent normal (OR = 1.823; P = ns, 95% confidence interval [CI] = 0.56-5.85). When comparing the allelic frequencies between patients with RCRT and adjacent normal, A allele was 3.2 times more prevalent in RCRT over adjacent normal (OR = 3.2; *P = .03, 95% CI = 1.08-9.98; Figure 4A ). mRNA/protein expression in the samples of each genotype (ie, GG, GA, and AA) is shown in Figure 4B ,C. The homozygous AA state was associated with greater reduction in Bax mRNA and protein expression.
Results represent the mean AE SD of the expression of Bax mRNA/protein in the samples with particular genotypes as indicated ( Figure 4D-F) .
3.5 | Bax protein expression and its association with p53, p-Akt, and Bcl-2
Western blot results showed detectable expression of the p53, p-Akt, and Bcl-2 proteins ( Figure 5A) Figure 5B -D. A negative correlation was observed between Bax protein expression and its regulatory molecules like p53, p-Akt, and Bcl-2 proteins (P = .04, .04, and .03, respectively, Figure 5E -G). Furthermore, a significant negative correlation of Bax mRNA with p53/p-Akt proteins (P = .02 and .04, respectively, Figure 5H ,I) was also observed.
| Correlation of Bax expression with p53 and p-Akt protein in oral cancer progression
The overall immunoreactivity/intensity was observed in adjacent sections of (n = 121) fresh samples, and p53/p-Akt was increased and the Bax immunoreactivity was decreased with oral tumor progression and drug resistance (Figure 6A -R; Supporting Information Table S1 ). In addition, the percentage p53 overexpression was 20.0%, 55.0%, and 81.4%, whereas that of p-Akt was 28.0%, 53.6%, and 77.7% in adjacent normal, primary tumor, and RCRT specimens, respectively (Supporting Information Table S1 ). Bax protein expression determined by IHC also correlated with the expression of p53 and p-Akt expression in adjacent regions. Statistically significant negative correlation was seen between Bax and p53 and p-Akt proteins in all the samples (P = .008 and .04, respectively, Figure 6S ) and in RCRT group of samples (P = .008 and .01, respectively, Figure 6S ). Figure 7A ). This was associated with elevated expression of Bax protein/mRNA ( Figure 7B-D) . Similarly, the decreased expression trend for pAkt and cell survival was also observed ( Figure 7E ,F) in both the cell lines. Figure 8A -F illustrates the effect of Akt inhibitor VIII and nimbolide both alone and in combination on Bax-induced apoptosis, as well as the expression of active caspase-3, p-Akt, p53, and cell survival analysis by MTT assay.
| DISCUSSION
OSCCs constitute more than 90% of all oral cancers. 1, 42 Chemotherapy, a common treatment modality for OSCC, often leads to chemoresistance and tumor recurrence. 3 Here,
we made an attempt to understand the proapoptotic Bax expression in OSCC progression and therapy resistance. Our results indicate overall decreased expression of Bax protein that paralleled with OSCC progression and drug resistance. Teni et al. reported decreased Bax expression in oral cancer specimens. 43 Besides this, the positive correlation of Bax mRNA expression with its protein expression suggests active transcriptional regulation of Bax gene in OSCC progression and resistance. We believe that promoter 49 These findings suggest the collapse of functional p53 pathway in OSCC. On the other hand, Akt activation promotes cell survival by phosphorylating and inactivating the proapoptotic protein Bax. 27 Alteration of Akt activity has been documented in several human cancers including OSCC. [24] [25] [26] Here, the negative correlation of Bax protein with its regulatory protein p-Akt was observed and was more significant in RCRT (n = 27; P = .01) indicating an important role for Akt activation in Bax-mediated drug resistance. Finally, the effect of Akt inhibitor VIII was tested in oral tongue cancer cell line (SCC9/ SCC4) and their cisplatin-resistant counterparts. In 2 separate previous studies, we demonstrated that Akt inhibitor VIII and nimbolide inhibit OSCC by targeting the Akt pathway. 33, 36 Here, we found that low dose of these reagents are efficacious in inducing mild apoptosis in both the SCC cells but not in SCC-CisR cells. On the other hand, a cumulative effect of Akt inhibitor VIII and nimbolide in inducing SCC9-CisR/SCC4-CisR cell death through the elevated expression of Bax was observed. Nimbolide efficiently blocked extracellular signal-regulated kinase (ERK) pathway in nasopharyngeal SCC through the induction of Bax. 34 Ji et al. reported higher expression of miR-128, a known upstream regulator of Bax in drug-resistant breast cancer samples. 50 Interestingly, lowering miR-128 led to enhanced Bax expression coupled with induction of chemosensitivity. 50 miR-128
is also linked to the PI3K/Akt pathway 51, 52 and p53 pathway. 53 Based on these reports and the results of the present study, we propose a model to explain the possible regulation of Bax in OSCC progression and resistance ( Figure 9 ). Although this study has identified the Akt-Bax pathway as an important target to treat drugresistant oral cancer, more work is needed to prove this conclusively. There are many off-target effects that the drugs utilized could have; hence an inducible system with upregulated Bax may be exploited in OSCC cell lines. Importantly, the present study lends credence to the inclusion of nimbolide as a natural compound with potential therapeutic efficacy against oral cancer, 54 as well as a promising candidate agent for overcoming cisplatin resistance.
